It is our mission to accurately predict treatment responses for cancer patients using powerful AI technology.
It is our mission to accurately predict treatment responses for cancer patients using powerful AI technology.
Founded in 2018 by frontline NHS Clinician and Oncologist Sola Adeleke, Curenetics brings together a diverse team of industry-leading specialists. Collaboration is central to our approach, combining the capabilities of practicing clinicians, AI engineers, data scientists, cancer biologists, and immunologists to tackle this single complex challenge.
Fundamental to our research is access to high-quality existing data sets. We gather and analyse patient genomics, imaging profiles, and clinical information from hospitals and labs, developing AI models that can layer these markers to produce uniquely accurate results.
Currently at the Proof-of-Concept stage, our model will integrate into established health systems to give patients and doctors a reliable, accurate, and cost-effective tool to make informed choices about cancer treatment options.
Curenetics also has a pipeline of AI-driven projects currently at the discovery stage, which include the diagnosis of oral cancer and the prediction of stem cell transplant rejection.
